Coloplast A/s Class B · OMXCOP:COLO_B

Coloplast A/s Class B — Q1 2014/15 Earnings Presentation

8 slides from Coloplast A/s Class B's earnings presentation, Jan 29, 2015

  1. Slide 1: Coloplast Earnings Conference Call Q1 2014/15

    Coloplast Earnings Conference Call Q1 2014/15 29 January 2015 Page 1

  2. Slide 2: Forward-looking statements

    Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements

  3. Slide 3: Disappointing organic sales growth in Q1 of 6% leads to revised guidance for fiscal year 2014/15

    Disappointing organic sales growth in Q1 of 6% leads to revised guidance for fiscal year 2014/15 Highlights Performance Revenue (mDKK)  Organic revenue growth of 6% (8% in DKK) Organic growth (%)  Gross margin of 69% - up 1% compared to 25,000 24,000 11 23,000 22,000 21,000 9 Q1 2013/14 20,000 19,

  4. Slide 4: Challenges emerged in the UK home care business and distributor buying patterns impacted US growth

    Challenges emerged in the UK home care business and distributor buying patterns impacted US growth Q1 14/15 revenue by geography Q1 14/15 revenue by business area Geographic Reported revenue Organic growth Business Reported revenue Organic growth area mDKK In percent area mDKK In percent European Os

  5. Slide 5: Operating margin of 32.6% driven by efficiency gains, negative product mix impact and sales investments

    Operating margin of 32.6% driven by efficiency gains, negative product mix impact and sales investments Highlights Q1 2014/15 Performance drivers Q1 2014/15  Q1 14/15 gross margin came in at 68.6% EBIT Margin Q1 2013/14 33.1%  Distribution to sales 29% up 0.3% ∆ Gross profit margin  Admin-to-sale

  6. Slide 6: Revised guidance for 2014/15 still points towards further market share gains and continued margin expansion

    Revised guidance for 2014/15 still points towards further market share gains and continued margin expansion Guidance Guidance Long term 14/15 14/15 (DKK) ambition Sales growth 8-9% (organic) 12-13% 7-10% p.a. EBIT margin ~34% (fixed) ~34% +50-100 bps p.a. CAPEX (DKKm) ~650 ~4-5% of sales Tax rate ~2

  7. Slide 7: Coloplast Capital Market Event 2015

    Coloplast Capital Market Event 2015 7 May 2015 in London ( tentatively from 1200-1800) We would like to provide institutional investors and financial analysts with the opportunity to meet with Lars Rasmussen, President & CEO, Anders-Lonning Skovgaard, EVP & CFO, Kristian Villumsen, EVP Chronic Care,

  8. Slide 8: Our mission, values and vision

    Our mission Making life easier for people with intimate healthcare needs Our values Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us Our vision Setting the global standard for listening and responding Coloplast

Coloplast — Q1 2014/15 Earnings Presentation on 6ix